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ABSTRACT
BTG2 is the prototypical member of the TOB
family and is known to be involved in cell growth,
differentiation and DNA repair. As a transcriptional
co-regulator, BTG2 interacts with CCR4-associated
factor 1 (CAF1) and POP2 (CALIF), which are key
components of the general CCR4/NOT multi-subunit
transcription complex, and which are reported to
play distinct roles as nucleases involved in mRNA
deadenylation. Here we report the crystal structures
of human BTG2 and mouse TIS21 to 2.3A ˚ and 2.2A ˚
resolution, respectively. The structures reveal the
putative CAF1 binding site. CAF1 deadenylase
assays were performed with wild-type BTG2 and
mutants that disrupt the interaction with CAF1.
The results reveal the suppressive role of BTG2
in the regulation of CAF1 deadenylase activity. Our
study provides insights into the formation of the
BTG2-CAF1 complex and the potential role of
BTG2 in the regulation of CAF1.
INTRODUCTION
Btg2, the anti-proliferative human homolog of the pc3
(rat) or tis-21 (mouse) genes, belongs to the BTG/TOB
family and was originally isolated as an immediate early
gene induced by tumor promoters and growth factors in
PC12 and Swiss 3T3 cells (1–3). The BTG/TOB family of
anti-proliferative proteins is composed of ﬁve structurally
related members in vertebrates, including BTG1, BTG2,
ANA/BTG3, TOB and TOB2 (4–6), which share signiﬁ-
cant sequence homology (Figure 1) and are reported to
be involved in cell growth, diﬀerentiation, and survival
(7–10).
Studies indicate that BTG2 should have a variety of
biological roles (6,11). These include: a transcriptional
co-regulator; diﬀerentiation; an anti-apoptotic factor in
neurogenesis (4,12–16); a key mediator of the stage-
speciﬁc expansion of thymocyte and a negative regulator
of hematopoietic progenitor expansion (17,18); a tumor-
suppressor gene in both mouse and human (19–21); a pan-
cell cycle regulator (13,22,23); and a regulator of embryo
development (24–26).
BTG2 exerts its biological functions by regulating
a variety of signaling pathways, which might be achieved
by its interaction with diﬀerent cellular targets via diﬀer-
ing mechanisms. As a transcriptional co-regulator, BTG2
has been shown to interact with CAF1 (CCR4-associated
factor 1) and POP2 (CALIF) (27,28), and works as a
co-activator of ERa-mediated transcription via a CCR4-
like complex (29). The main role of the CAF1 homolog in
yeast was presumed to be related to its interaction with
CCR4, as the CAF1 protein isolated from Saccharomyces
cerevisiae did not possess deadenylase activity (30,31). As
recombinant yeast CAF1 extracted from Escherichia coli
degraded poly(A) in vitro, and CAF1 deletion mutants in
yeast show a deadenylation defect, yCAF1 was believed
to be required for normal mRNA deadenylation in vivo
(31,32). Recently, trypanosome CAF1 was reported to
have deadenylation activity, and its depletion led to the
delay of deadenylation and degradation of constitutively
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Drosophila cells, in which depletion of CAF1 brought a
marked increase in average poly(A) length and the rate
of deadenylation of Hsp70 mRNA was strongly reduced
during the recovery from heat shock (34). Mouse CAF1
was identiﬁed through its interaction with the CCR4 pro-
tein, which can complement the yeast pop2 null mutation
in some aspects, and which acts as a processive deadeny-
lase in vitro (35–37). The deadenylase activity of yeast
POP2, which is related to RNaseD, is evolutionarily con-
served in the CAF1 family including the human homologs
CAF1 and POP2 (32,33,38).
There are a number of other known molecular targets of
PC3/TIS21/BTG2 in addition to CAF1 and POP2, includ-
ing PRMT1 (Protein arginine N-methyltransferase 1) (39),
Homeoprotein HOXB9 (40), CyclinB1 associated protein
kinase Cdc2 (41), Smad1 and Smad8 (24) and Pin-1
(Peptidyl prolyl cis/trans isomerase) (23). Previous studies
indicate that BTG2 can modulate the activities of some of
its interacting partner proteins, either by stimulation or
suppression (24,39–41).
As the prototypical member of an anti-proliferative
family, BTG2 contains three highly conserved domains
among various species; Box A (Y50–N71), Box B
(L96–E115) (4,5) and Box C (D116-P127). Box A, which
is also named GR (for growth regulatory, corresponding
to residues Y50-I68 in TIS21), and Box B respectively
appear to play key roles in anti-proliferative function
and in binding to a number of molecular targets (13,27).
There are two copies of an LXXLL motif in BTG2 that
are involved in the regulation of ERa-mediated activation:
L1 (L42-L46) and L2 (L92-L96), referred to as the NR
(nuclear receptor) box (28,42). Moreover, Box C is known
to interact with PRMT1 in vitro (43).
However, little is known about the precise role of BTG2
in the deadenylase activity of CAF1. Here we report the
crystal structures of human BTG2 and the mouse homo-
log TIS21 to 2.3A ˚ and 2.2A ˚ resolution, respectively. The
structures reported here reveal features that are important
for interaction with their molecular targets. Based on our
preliminary structural analysis, wild-type BTG2 and sev-
eral mutants were constructed for interaction assays and
deadenylase assays, the results of which reveal that BTG2
plays a suppressive role in the regulation of CAF1 dead-
enylase activity. These data provide a structural basis for
further analysis of BTG2 in the formation of the BTG2–
CAF1 complex and the regulation of CAF1 activity.
MATERIALS AND METHODS
Proteinexpression andpurification
The coding sequences of the human BTG2 and mouse
TIS21 genes were inserted into the bacterial expression
vector pGEX-6P-1 (GE Healthcare) using EcoRI and
XhoI restriction sites. The recombinant plasmids of
human BTG2 and mouse TIS21 were transformed into
the E. coli strain BL21 (DE3) and overexpressed as
Figure 1. Sequence alignment of human BTG2 with homologous proteins. From ‘top’ to ‘bottom’, the sequences are BTG2 from Homo sapiens
(NP_006754), TIS21 from Mus musculus (NP_031596), BTG1 from Homo sapiens (NP_001722), Tob1 from Homo sapiens (NP_005740), Tob2 from
Homo sapiens (NP_057356) and BTG3 from Homo sapiens (NP_006797). The secondary structure of human BTG2 is indicated in the top line, as well as
the conserved domains in the bottom line. Box A, Box B and Box C are shown enclosed by a blue box, while the two LXXLL motifs are shown by a white
box. Strictly conserved residues among TOB family members are indicated in red and the most conserved residues are highlighted in red. Residues
involved in CAF1 binding are labeled with magenta stars. Sequences were aligned using CLUSTALW(58) and the Figure was producedwith ESPript (59).
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ble GST-tagged proteins were puriﬁed by GST-glu-
tathione aﬃnity chromatography. GST-tagged proteins
were employed for in vitro GST ‘pull-down’ experiments,
while proteins cleaved with PreScission Protease at 168C
overnight were subjected to further puriﬁcation.
Recombinant human BTG2 was further puriﬁed using
Resource S (GE Healthcare) and Superdex-200 size-
exclusion columns (GE Healthcare). The puriﬁed and
concentrated human BTG2 protein (4–6mg/ml) was
stored in 20mM MES (pH 5.6), 70mM NaCl at  808C.
Recombinant mouse TIS21 was puriﬁed in a similar
manner and stored in 20mM HEPES (pH 7.5), 70mM
NaCl at –808C.
Mutations of several key residues in the CAF1-binding
interface of human BTG2, including Y65A, W103A,
D105A, E115A and G64A-W103A were introduced by
the PCR method using the human BTG2 expression plas-
mid as a template, with pairs of primers encoding the
mutations at the sites of substitution. All mutants were
cloned into the expression plasmid pGEX-6P-1 and over-
expressed and puriﬁed following a similar protocol to
wild-type BTG2. The wild-type and mutants of human
BTG2 were also sub-cloned into the vector of pME18S-
GST for in vivo interaction assay.
Human CAF1 and POP2 were also cloned into the
pGEX-6P-1 vector. The soluble GST-CAF1 and GST-
POP2 proteins were puriﬁed by GST-glutathione aﬃnity
chromatography and cleaved with PreScission Protease at
168C overnight. Recombinant human CAF1 and POP2
were further puriﬁed using Resource Q (GE Healthcare)
and Superdex-200 size-exclusion columns (GE Health-
care) using a buﬀer containing 20mM HEPES (pH 7.5),
150mM NaCl. The puriﬁed and concentrated human
CAF1 and POP2 proteins were stored in the deadenylase
buﬀer (50mM Tris–HCl, 150mM NaCl, 10% glycerol,
1mM DTT at pH 7.5) at –808C.
Crystallization
The human BTG2 protein solution used for crystallization
contained 20mM MES (pH 5.6), 70mM NaCl and
4mg/ml protein. Optimal crystals were obtained using
the hanging-drop, vapor-diﬀusion technique with reser-
voir solutions containing 100mM Bis–Tris (pH 6.1),
0.2M sodium chloride, 21% (v/v) PEG3350. Protein solu-
tion (1.0ml) was mixed with reservoir solution (1.0ml) and
equilibrated against 300ml of reservoir solution at 168C.
The mouse TIS21 protein solution used for crystalliza-
tion contained 20mM HEPES (pH 7.5), 70mM NaCl and
6mg/ml protein. The reservoir solution contained 100mM
Bis–Tris (pH 6.5), 23% (v/v) PEG3350. Crystals were
obtained following the same method as described for
human BTG2.
Data collection and processing
Native crystals of human BTG2 for data collection
were ﬂash-cooled in liquid nitrogen in the crystallization
reservoir solution and diﬀracted to 2.3A ˚ resolution.
Data were collected on beamline BL5 of the Photon
Factory (Tsukuba, Japan) using an ADSC-Q315 detector.
The program HKL2000 was used for data processing,
integrating, merging and scaling (44). The crystal
belongs to the orthorhombic space group P212121 with
unit cell parameters a=39.39, b=40.56, c=67.48A ˚ ,
==g=908. There is one BTG2 monomer per asym-
metric unit, with a solvent content of 18.6% and a
Matthews coeﬃcient of 1.51 A ˚ 3 Da
–1 (45).
Native crystals of mouse TIS21 diﬀracted to 2.2-A ˚ reso-
lution. Data were collected in-house on a Mar345dtb
image plate with a Rigaku MM007 rotating CuKa
anode X-ray source. The crystal belongs to the same
space group with unit cell parameters a=38.02,
b=39.70, c=83.70A ˚ ,  =  = g =9 0 8. There is also
one molecule per asymmetric unit, with a solvent content
of 30% and a Matthews coeﬃcient of 1.75 A ˚ 3 Da
 1.
Structure determination and refinement
For structure determination of human BTG2, the phasing
problem was solved by the MR method using the program
Phaser in the CCP4 program suite (46). The structure
of TOB from the TOB-CAF1 complex (PDB entry
2D5R) (47), which shares 40% sequence identity with
human BTG2, was employed as a search model. The
human BTG2 model was manually adjusted with COOT
and reﬁned with Refmac5 (48,49). The ﬁnal model is com-
posed of one BTG2 monomer, with 120 residues (from
residues 7 to 127) and 55 water molecules. The structure
of mouse TIS21 was also solved by MR following the
same protocol and using the same search model. The
ﬁnal TIS21 model includes 117 residues (from residues
8 to 125) and 82 water molecules. Data collection and
structure reﬁnement statistics are summarized in Table 1.
GST ‘pull-down’ experiments in vitro
Following removal of the GST tag, recombinant CAF1
protein puriﬁed from E. coli was incubated with GST—
and GST-BTG2 WT/mutant—-glutathione-Sepharose
beads overnight at 48C. After washing ﬁve times with
the binding buﬀer (PBS with 1% Triton X100), the
retained proteins were analyzed on a 12% SDS–PAGE
gel and immunoblotted with an anti-CAF1 antibody (50).
Expression vectorsand transient transfection
CAF1 and BTG2 cDNAs (wild-type and several mutants)
were inserted into pME18S-Flag and pME18S-GST vec-
tors, respectively. Cos 7 cells were transfected with various
combinations of the expression vectors by FuGene 6
(Roche) according to manufacturer’s protocol. The
amount of transfected DNA was adjusted in each experi-
ment by using a control expression vector.
Immunoprecipitation and immunoblotting
In brief, 2 days after transfection, Cos 7 cells were lysed
with TNE buﬀer [20mM Tris–HCl (pH 7.5), 150mM
NaCl, 1% NP-40, 1mM EDTA, 10mM NaF, 1mM phe-
nylmethylsulfonyl ﬂuoride]. Lysates were incubated with
glutathione-Sepharose beads for 2h at 48C. After washing
ﬁve times with TNE buﬀer, the GST-precipitates as well as
the lysates were immunoblotted with anti-Flag antibody
6874 Nucleic Acids Research, 2008, Vol. 36, No. 21(M2:Sigma) and anti-GST antibody (Santa Cruz
Biotechnology).
Deadenylase assays
The wild-type and mutant human BTG2 proteins, human
CAF1 and POP2 were puriﬁed as described and dialyzed
against the deadenylase buﬀer (50mM Tris–HCl, 150mM
NaCl, 10% glycerol, 1mM DTT, 5mM MgCl2 at pH 7.5).
These proteins were incubated at 378C for 40min with a
synthesized poly(A) RNA substrate (50-UCUAAAUAAA
AAAAAAAAAAAAAAAAA-30; ﬁnal concentration
0.5mM) labeled with ﬂuorescein isothiocyanate at the 50
end (51). After addition of formamide, the reaction mix-
tures were fractionated on a 7M urea-25% sequence poly-
acrylamide denaturing gel. The products were analyzed
and quantiﬁed with a ﬂuorescence imager, FLA-5000
(FUJIFILM).
RESULTS
Overview ofthe human BTG2 andmouse TIS21 structures
Human BTG2 has approximate dimensions of
49 40 29 A ˚ 3 (Figure 2a). The structure is comprised
of ﬁve a-helices and four b-strands that form two anti-
parallel b-sheets. The N-terminal six residues of human
BTG2 are ﬂexible and could not be located from electron
density maps. Thr7, the ﬁrst observable residue, leads
immediately into a bundle of three a-helices, followed
by four b-strands with two small a-helices inserted
between strands b1 and b2. The mouse TIS21 structure
is also composed of ﬁve a-helices and four b-strands.
A
B
C
Figure 2. Structures of human BTG2 and mouse TIS21. (A) Ribbon
diagram of human BTG2. The conserved domains of Box A, Box B,
Box C and the putative HOXB9 interaction region are colored in cyan,
yellow, magenta and wheat respectively. The two LXXLL motifs are
shown as L1 and L2 motif in black frame. (B) Superposition of human
BTG2, mouse TIS21 and TOB (PDB code 2D5R). Human BTG2 is
colored in green, mouse TIS21 in yellow and TOB in purple. The
regions of the three structures exhibiting main diﬀerences are indicated
in the red rectangle. The close-up view is shown to the right. The amino
acid positions where TOB diﬀers from BTG2/TIS21 are represented as
sticks. (C) The conservation of the residues of BTG2/TOB involved in
CAF1 binding. CAF1, TOB and BTG2 molecules are colored in gray,
violet and blue, while CAF1 is shown in ‘Surface’ diagram. Conserved
residues of BTG2at the interaction surface are represented as sticks.
Table 1. X-ray data collection and structure reﬁnement statistics for
human BTG2 and mouse TIS21
Parameter Mouse TIS21 Human BTG2
A. Data collection
Space group P212121 P212121
Cell dimensions a/b/c (A ˚ ) 38.02/39.70/83.70 39.39/40.56/67.48
Wavelength (A ˚ ) 1.5418 1.0000
Resolution (A ˚ ) 50–2.2 (2.28–2.20) 50–2.3 (2.34–2.26)
Average I/s (I)
a 16.4 (3.6) 31.5 (4.2)
Total reﬂections 47147 26145
Unique reﬂections 6868 5309
Completeness (%)
a 100 (100) 97.6 (95.1)
Rmerge (%)
a,b 11.5 (46) 5.7 (21.3)
B. Structure reﬁnement
Resolution (A ˚ ) 50–2.2 50–2.3
Average B-factor (A ˚ )
b 29.7 37.5
Rwork/Rfree (%)
c 22.1/25.0 19.4/26.3
R.m.s.d. bond lengths (A ˚ )
d 0.006 0.014
R.m.s.d. bond angles (8)
d 1.265 1.452
C. Ramachandran plot
Most favored (%) 91.2 89.4
Allowed (%) 7.8 9.6
Generously allowed (%) 1.0 1.0
Disallowed (%) 0 0
aNumbers in parentheses correspond to the highest-resolution shell.
bRmerge =Si |Ii-hIi|/ShIi, where Ii is an individual intensity measure-
ment and hIi is the average intensity for all the reﬂections.
cRwork/Rfree = S ||Fo|-|Fc||/S|Fo|, where Fo and Fc are the observed and
calculated structure factors, respectively.
dR.m.s.d. relate to the Engh and Huber parameters.
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and mouse TIS21. With a primary sequence identity of
93%, the crystal structures of human BTG2 and mouse
TIS21 share an r.m.s.d. of 0.6A ˚ for the 117 aligned Ca
atoms. Superposition of the backbones of human BTG2
and mouse TIS21 is shown in Figure 2b.
The structure clearly shows the three highly conserved
domains. Box A is composed of strand b1, the short helix
a3, part of the a2 helix and a connecting loop between
them. Two antiparallel b-strands (b2 and b3) form Box B,
while Box C is composed of strand b4 and the extended
C-terminal loop. Helix a1, part of the a2 helix and the
connecting loop between them constitute the putative
HOXB9 interaction region. Previous studies have shown
that BTG2 can associate with various molecular targets
via diﬀerent regions (27,40,43). Consistent with our struc-
ture, these interfaces are located on diﬀerent surfaces of
BTG2 and may not interfere with each other, which raises
the possibility that BTG2 may bind two or more molecu-
lar targets simultaneously in order to fulﬁll diﬀerent
regulatory requirements.
The two LXXLL motifs known as the nuclear
receptor box (NR box) are located on helices a2 and a5,
respectively. Interestingly, these two motifs are located on
opposing faces of BTG2 and provide a hydrophilic sur-
face, which might facilitate contact with nuclear receptors,
while the hydrophobic residues are buried inside the core
of the protein. The leucine residues of the NR box are
located in the middle of their respective a-helices.
Locationof theputative CAF1 bindingsite
The primary sequence identity between human BTG2 and
human TOB is 40%, and their structures share an r.m.s.d
of 1.2A ˚ for 114 aligned residues. Superposition of the
backbones of human BTG2 and TOB (PDB code 2D5R,
unpublished data) is shown in Figure 2b. Previous studies
have highlighted the importance of Box B of the TOB
family proteins for interaction with CAF1 (27), while the
TOB–CAF1 complex structure shows that both Box A
and Box B participate in association with CAF1.
Structural comparison of the interaction surfaces of
BTG2 and TOB reveals signiﬁcant conservation of the
CAF1 interface (Figure 2c), as predicted by the conserva-
tion of sequence in these domains. In our crystal structure
of human BTG2, the Tyr65 residue in Box A orients its
polar NH2 group against the outside of the hydrophilic
cluster, while its aromatic side chain is buried inside and
may form hydrogen bonds with CAF1; the Trp103 residue
projects out its aromatic side chain which may participate
in strong hydrophobic interactions with CAF1; the
Asp105 residue is located in a cavity that may form the
entrance to CAF1; and the Glu115 residue forms a protu-
berant head which may bind into a groove on the CAF1
molecule but with a weaker association. As a result, we
speculate that Tyr65 in Box A and Trp103 and Asp105 in
Box B may be important for the interaction of BTG2 with
CAF1, while Glu115 alone may not play a predominant
role. In order to test this hypothesis, several conserved
residues (Y65, W103, D105 and E115) were individually
mutated to alanine and the resulting mutant proteins were
assayed for their ability to bind to CAF1. Due to the poor
stability of the BTG2 W103A mutant in E. coli, a G64A-
W103A double mutant was constructed for interaction
assays and subsequent deadenylase assays. First, the
in vitro interaction assays of BTG2 wild-type and mutants
with CAF1 were performed by GST ‘pull-down’
(Figure 3). As mentioned before, in respect to the poor
stability of BTG2 W103A and D105A mutants in E. coli,
only wild-type BTG2 and Y65A, E115A and G64A-
W103A mutants were applied for in vitro interaction
assays. The results show that both the Y65A and G64A-
W103A mutants were unable to interact with CAF1
in vitro. In contrast, the E115A mutant appeared to
retain some binding to CAF1. For further conﬁrmation,
we performed co-immunoprecipitation experiments of
CAF1 with wild-type BTG2 and the mutants Y65A,
W103A, D105A, E115A and G64A-W103A. A vector
expressing Flag-tagged CAF1 was transfected into Cos 7
cells, together with a GST-tagged expression vector encod-
ing GST-tagged BTG2 wild type or mutants. Lysates of
transfectants were applied for pull-down with glutathione-
Sepharose beads, followed by immunoblotting with anti-
Flag antibody (Figure 4). Only the wild-type BTG2 and
E115A mutant were observed to interact with Flag-CAF1,
while no interaction was seen for the Y65A, W103A,
D105A and G64A-W103A mutants. The in vivo and
in vitro interaction assays consistently demonstrated that
the missense mutations Y65A, W103A or D105A resulted
Figure 3. Interaction of CAF1 with wild-type Btg2 and mutants
in vitro. CAF1 protein was incubated with GST and GST-BTG2
wild-type and mutants. The retained proteins were analyzed by immu-
noblotting with an anti-CAF1 antibody. The aliquots of GST-fusion
proteins used in the upper panel were subjected to gel electrophoresis
and CBB staining which were shown in the bottom.
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In agreement with our hypothesis, the residues Y65 in
Box A and W103, D105 in Box B of BTG2 are critical
for interaction with CAF1. Only one single point mutation
will abolish the interaction between BTG2 and CAF1.
Although the main chain amide group of Tyr65 in
BTG2, rather than the side chain, may mediate its invol-
vement in the interaction with CAF1, the side chain does
play important roles as an anchor. Compared with the
Phe55 residue of TOB, the Tyr65 residue of BTG2 has
an additional hydroxyl group which can form an intramo-
lecular hydrogen bond with the His49 residue. The hydro-
gen bond between Tyr65 (on helix a3) and His49 (on helix
a2) helps to anchor Tyr65 and facilitates the a-helical
bundles, which lie behind, to provide support and stability
to the CAF1 interface. Thus if the side chain of Tyr65
residue is lost, the residue will become too ﬂexible and
may no longer be strong enough to exert a force on
CAF1. This may explain why the Y65A mutant causes a
signiﬁcant loss-of-interface interactions compared with
the wild-type BTG2. Glu115 is further away from CAF1
than other main residues in the BTG2-CAF1 interface. In
agreement with our prediction, the role of Glu115, in
interaction with CAF1 is not as crucial as Trp103 since
there is no observed reduction in the CAF1 binding aﬃ-
nity of the E115A mutant. The rapid degradation of the
W103A mutant suggests that Trp103 not only plays
important roles in the formation of the BTG2-CAF1 com-
plex, but also contributes to the stability of BTG2. From a
careful analysis of the crystal structure of human BTG2, it
is evident that the residues discussed above at the interface
all ﬁt the electron density map very well and their mean
temperature factors are not high, implying that the orien-
tation of these residues in our structure is correct and
credible.
BTG2suppresses thedeadenylase activity of CAF1
To examine whether BTG2 aﬀects the mRNA deadenyla-
tion mediated by CAF1, we carried out in vitro deadeny-
lase assays with single-strand poly(A) RNA as a substrate.
We ﬁrst examined the deadenylase activity of CAF1.
GST-tagged CAF1 was over-expressed in E. coli cells,
and the soluble GST-tagged proteins were puriﬁed by
GST-glutathione aﬃnity chromatography and cleaved
with PreScission Protease at 168C overnight. The CAF1
proteins were further puriﬁed using a Resource Q ion
exchange column and a Superdex-200 size-exclusion
column. The puriﬁed and concentrated CAF1 proteins
(Figure 5a) were diluted in the deadenylase buﬀer and
incubated with a poly(A) RNA substrate at 378C for
40min. Analysis of the reaction products on the denatur-
ing sequencing gel revealed cleavage of the poly(A) RNA
substrate (Figure 5b). The generation of an RNA ladder,
which indicated trimming of the substrate from the 30-end
due to the 50-end label, conﬁrmed that CAF1 had dead-
enylase activity in vitro.
Recombinant human BTG2 was overexpressed and
puriﬁed in a similar manner, albeit using a Resource S
ion exchange column for puriﬁcation in place of the
Resource Q ion exchange column. When puriﬁed wild-
type BTG2 protein was added to the deadenylase reaction
system of CAF1 in increasing amounts, the deadenylase
activity of CAF1 was suppressed in a dose-dependent
manner, while the Y65A and G64A-W103A mutants had
no eﬀect on the deadenylase activity of CAF1 (Figure 5b).
Figure 5b also shows that the wild-type BTG2 and mutants
alone had no deadenylase activity. Deadenylase assays
were also performed with another BTG2 mutant, E115A,
which can still interact with CAF1, with similar suppres-
sion of CAF1 activity as for the wild-type BTG2
(Figure 5c). The above data suggest that BTG2 both qua-
litatively and quantitatively suppresses CAF1 activity, and
that the suppressive role of BTG2 may be achieved via the
direct interaction of these two proteins. Consistent with
previous data, BTG2 mutants shown not to interact with
CAF1 also failed to suppress CAF1 activity. The BTG2
E115A mutant, which could still associate with CAF1, also
suppressed CAF1 activity similar to the wild-type protein.
Similar results were obtained to show that BTG2 also
suppressed the deadenylase activity of CALIF/Pop2
(Figure 5d). The data from Figure 5d suggest that this
suppressive role of BTG2 towards the CAF1 family of
proteins is conserved.
DISCUSSION
Comparison withrelated structures
A search for similar structures with the DALI server (52)
did not yield any other matches for BTG2 besides the TOB
Figure 4. Interaction of CAF1 with BTG2 wild-type and the mutants
in vivo. Cos 7 cells were transfected with the plasmids coding for Flag-
tagged CAF1 and GST-tagged BTG2 wild-type or mutants. Cell lysates
were prepared 48h after transfection. Interactions were examined by
pull-down with glutathione-Sepharose beads, followed by immunoblot-
ting (IB) with anti-Flag antibody and anti-GST antibody. Expression of
Flag-tagged CAF1 is shown in the bottom.
Nucleic Acids Research, 2008, Vol. 36, No. 21 6877structure (PDB entry 2D5R), which belongs to the same
family. This suggests that structures of the TOB family are
highly conserved but quite distinct from other proteins.
Interestingly, in contrast to the tight loop between helices
a1 and a2 of TOB, BTG2 contains a more ﬂexible loop
(T26-G28) that may be important for its interaction with
molecular targets such as HOXB9. It has been reported
that the N-terminal region of BTG1 (1–38), whose corre-
sponding residues are 1–36 in BTG2, is suﬃcient for inter-
action with HOXB9 using the yeast two-hybrid system
(40). However, there are no reports of a direct interaction
between HOXB9 and TOB to date. Thus, we postulate that
the ﬂexible loop between helices a1 and a2 of BTG2 is
likely to be important for contact with HOXB9.
Despite belonging to the same family, BTG2 and TOB
have diﬀerent molecular targets and are involved in
diverse signaling pathways. Therefore, the subtle diﬀer-
ences between these two protein structures may provide
a basis to explain their diﬀerent functions. Nevertheless,
we cannot rule out the possibility that diﬀerences in
expression may also contribute to these eﬀects.
A modelof BTG2–CAF1 complex
Combined with all the data above, we built a three-dimen-
sional model of the BTG2-CAF1 complex by FTDOCK
(53). Our model suggests a total of  1400 A ˚ 2 of solvent
accessible surface area on the two proteins would be
buried as a result of complex formation. The BTG2–
CAF1 interface would involve hydrophobic, charged and
polar residues together with an elaborate network of
hydrogen bonding, constituting two main patches of inter-
actions. For clarity, the CAF1 and BTG2 interface resid-
ues are subscripted with A and B, respectively. In the ﬁrst
patch, the amide group of TyrB65 would form a hydrogen
bond with the O atom of PheA245. The second patch
would consist of the TrpB103 and AspB105 residues and
the Ser201A and Lys203A residues. Of these, the TrpB103
residue would be highlighted as the core of the interface
that would make extensive contacts both through the
hydrophobic interaction and hydrogen bonds with
CAF1. Speciﬁcally, the aromatic ring of the TrpB103 resi-
due would form a typical –cation interaction with the
Lys203A residue, and the Ne1 atom of TrpB103 would
form a hydrogen bond with the O atom of Ser201A.
Moreover, the AspB105 residue would form a salt bridge
with the Lys203A residue. Taken together, our model indi-
cates that there would be two invariant residues (Trp103
and Asp105) and one conserved residue (Tyr65) of BTG2
in close contact with CAF1. Although our model ﬁts the
two protein molecules reasonably well and is consistent
A
B
C
D
Figure 5. The deadenylase assay of CAF1/POP2 with BTG2 wild-type
and mutants in vitro.( A) Protein proﬁle of the CAF1, POP2, BTG2
wild-type and mutants Y65A, G64A-W103A and E115A. The migra-
tion of a molecular weight size marker is indicated. According to the
result of CBB staining and UV spectrophotometer, proteins were
diluted to the same concentration for deadenylase assay. (B) CAF1
only or CAF1 with BTG2 wild-type or G64A-W103A or Y65A
mutant proteins were incubated with 50-ﬂuorescein isothiocyanate-
labeled RNA substrate (RNA 30-7N+20 As) for 40min. (C) CAF1
only or CAF1 with BTG2 E115A mutant were employed for deadenyl-
ase assays as described. (D) POP2 alone or POP2 with wild-type BTG2
were employed for deadenylase assays as described. The labeled RNA
was then analyzed on a denaturing sequencing gel. The control lane
shows the starting substrate; the concentrations of CAF1 and POP2
applied in this assay were all 0.5mM.
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binding cannot be excluded.
Interestingly, our experiments reveal that BTG2 sup-
presses the deadenylase activity of CAF1 via direct inter-
action. However, the interface of BTG2 and CAF1 is not
close to the active site of CAF1. One possibility would be
that the binding of BTG2 is enough to induce local con-
formational changes that inﬂuence the activity of CAF1 or
even distort the active site. Some previously published
examples have highlighted the conformational rearrange-
ments of enzymes upon complex formation, such as the
Trm8–Trm82 complex and HP1451–HP0525 complex
(54,55). Trm8, the catalytic subunit of a yeast m7G46
tRNA methyltransferase, undergoes subtle conforma-
tional changes upon binding the noncatalytic subunit
Trm82, which results in the regulation of Trm8 activity
(54). HP1451 binds to HP0525, which is an inner mem-
brane associated ATPase, inducing notable changes in the
HP0525 structure; it therefore acts as an inhibitory factor
(55). However, the proteins in our complex model are
regarded as rigid molecules in docking and we cannot
derive any information about their conformational ﬂex-
ibility. BTG2 lacks any known RNA-binding domains
and may not directly interact with RNA. Nevertheless, it
is tempting to speculate that BTG2 may block access of
CAF1 to RNA for cleavage, particularly for longer RNA
substrates, and this may provide an alternative potential
mechanism for the suppression of CAF1 deadenylase
activity. It will be of interest to determine whether
BTG2 blocks the substrate binding of CAF1 and thus
explain how BTG2 contributes to the suppression of the
deadenylase activity of CAF1.
BTG2 was recently shown to be a general activator of
mRNA degradation, for which the deadenylase activities
of both CAF1 and CCR4 are involved (56). However, the
precise mechanism by which BTG2 enhances mRNA
deadenylation remains to be determined, as BTG2 was
unable to trigger the deadenylase activity of CAF1
in vitro (56). We have demonstrated that BTG2 could
suppress the deadenylase activity of CAF1 in vitro.W e
recently showed that TOB interacts with the CCR4–
NOT complex and inhibits its deadenylase activity
in vitro (57). Therefore, at least in vitro, the TOB/BTG
family proteins inhibit deadenylase activity associated
with the CAF1-containing CCR4–NOT complex. It is
apparent that CAF1 by itself is not the decisive factor in
mRNA deadenylation, and alternative pathways of cellu-
lar mRNA decay may unusually operate when its dead-
enylase activity is suppressed by BTG2. One possibility
would be that CAF1 may release the mRNA substrate
and transfer it to other deadenylases such as Pan2-Pan3.
Further studies would help understand the contradictory
roles of BTG2 on mRNA decay between in vivo and
in vitro, and clarify the complicated pathways and net-
work of cellular mRNA turnover.
CONCLUSIONS
In summary, our structural analysis of BTG2 provides
useful insights into the putative CAF1-binding interface
and indicates the main diﬀerence with TOB, which may
explain the diﬀerent roles of these two pleiotropic pro-
teins, and suggest how the BTG2–CAF1 complex may
form. The deadenylase assay of CAF1 with BTG2 pro-
vides an unexpected insight into the suppressive role
of BTG2, which is the ﬁrst to reveal the precise role of
BTG2 to CAF1.
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